TICKERNERD
Menu
ECORECORHealthcare · Medical Devices

ECOR Stock Forecast: electroCore, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$9.62
+4.68% on the day

The 5 Wall Street analysts covering electroCore, Inc. hold a median 12-month price target of $20 — +106.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 11 Sept 2026 — in the upper half.

Market cap
$86.7M
Ticker Nerd rank
59 / 100
Median analyst target
$20
Analysts covering
5
Revenue$9.4M+28.0% y/y
Operating income−$2.8M
Net income−$3.1M
Free cash flow−$3.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.5%
1M
+5.5%
YTD
+114.5%
1Y
+91.6%
From 52W high
−11.0%
From 52W low
+117.6%
$4
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ECOR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores electroCore, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
87
Revisions
82
Size
77
Accruals
58
Quality
55
Growth
44
Value
41
Volatility
16
Issuance
7

Momentum (87): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ECOR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ECOR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26ECORHigh $26Median $20Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $12Median $20High $26

The green dot is the last close — the median target sits +106.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
26 Jan 2026HC Wainwright & Co.MaintainsBuy$25 → $18
26 Jan 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025Ladenburg ThalmannMaintainsBuy—
18 Dec 2024HC Wainwright & Co.MaintainsBuy—
14 Mar 2024HC Wainwright & Co.ReiteratesBuy—
22 Jan 2024HC Wainwright & Co.MaintainsBuy—
9 Nov 2023HC Wainwright & Co.MaintainsBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
4 May 2023HC Wainwright & Co.MaintainsBuy—
18 Apr 2023CG CapitalReiteratesOutperform—
18 Apr 2023HC Wainwright & Co.MaintainsBuy—
9 Mar 2023HC Wainwright & Co.ReiteratesBuy—
13 Jan 2023Brookline CapitalInitiatesBuy$1.25
19 Jan 2022HC Wainwright & Co.MaintainsBuy$3.00 → $2.75
27 July 2021Ladenburg ThalmannInitiatesBuy—
23 Oct 2020Brookline CapitalInitiatesBuy—
30 Sept 2020Maxim GroupInitiatesBuy—
14 Aug 2020BTIGUpgradeBuy—
14 Aug 2020HC Wainwright & Co.MaintainsBuy$2.50 → $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ECOR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ECOR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, electroCore, Inc. returned +91.6% against +17.5% for the S&P 500, dividends included.

ECOR vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26ECORS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ECOR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

electroCore, Inc. (ECOR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.9×

Cheaper than 90% of US stocks

Price / sales
2.3×

Cheaper than 49% of US stocks

Price / book
−32.8×

Cheaper than 99% of US stocks

EV / EBITDA
−6.3×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
28.0%

Higher than 77% of US stocks

Earnings growth (YoY)
28.0%

Higher than 64% of US stocks

Gross margin
86.5%

Higher than 95% of US stocks

Operating margin
−29.3%

Higher than 20% of US stocks

Net margin
−40.0%

Higher than 12% of US stocks

Returns & dividend
Return on equity
817.2%

Higher than 99% of US stocks

Return on assets
−55.0%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

electroCore, Inc. (ECOR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • electroCore, Inc. has a market value of $86.7M and an enterprise value of $86.3M.

  • Revenue in the twelve months to 30 June 2026: $37.0M. The latest quarter grew 28.0% year on year.

  • Net income over the same four quarters: −$14.8M, a −40.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$9.7M.

  • Shares outstanding: 9.0M.

  • Trailing P/E: −5.9×; forward P/E: −17.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • electroCore, Inc. employs 83 people — $445K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ECOR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ECORelectroCore, Inc.$86.7M
59
HYPRHyperfine, Inc.$83.8M
50
LNSRLENSAR, Inc.$90.7M
62
SERASera Prognostics, Inc.$79.5M
41
MBOTMicrobot Medical, Inc.$97.4M
15
LUNGPulmonx Corp.$76.3M
82
CVRXCVRx, Inc.$75.8M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own electroCore, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ECOR news & analysis

electroCore to Participate at H.C. Wainwright Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

electroCore, Inc. (Nasdaq: ECOR) announced that its management will participate in the H.C. Wainwright Global Investment Conference. The company is a commercial-stage bioelectronic medicine and wellness firm based in Rockaway, New Jersey.

Why it matters — Participation at a major investment conference gives ECOR management a platform to present the company's business to investors, which ECOR watchers may follow for visibility.

electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers

GlobeNewsWire · 9 Sept 2026neutral

electroCore, Inc. has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, effective September 8, 2026. The appointments were announced by the company on September 9, 2026.

Why it matters — A change in top leadership with the appointment of two co-CEOs is a significant governance development for electroCore that investors may want to monitor.

electroCore's Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards

GlobeNewsWire · 25 Aug 2026positive

electroCore's Truvaga was named Best Luxury Biohacking & Longevity Brand in the USA by the Luxury Lifestyle Awards. The recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design, and a personalized wellness experience.

Why it matters — This external recognition could raise brand visibility and credibility for electroCore's Truvaga product in the wellness market.

electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

electroCore, Inc. (ECOR) held its Q2 2026 earnings call, the transcript of which was published on Seeking Alpha. The call covered the company's second-quarter 2026 financial results and business update.

Why it matters — A transcript of the Q2 2026 earnings call provides ECOR watchers with a detailed account of management's commentary on the company's recent performance and outlook. Can I add more? The instruction says why_it_matters 1 sentence. That seems fine. But I should keep neutral. Good.

electroCore Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

electroCore reported second-quarter 2026 revenue of $9.5 million, up about 28% from $7.4 million a year earlier, driven by growth in Veterans Affairs prescription sales and direct-to-consumer Truvaga sales. The company raised its full-year revenue outlook to growth of more than 30% over 2025 and said it is targeting positive adjusted EBITDA in the third quarter of 2027.

Why it matters — The revenue growth, raised full-year outlook, and adjusted EBITDA target indicate improving financial momentum for ECOR watchers.

FAQ

Frequently asked questions about ECOR stock

What is the ECOR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering electroCore, Inc. have a median 12-month price target of $20, with estimates ranging from $12 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ECOR stock a buy right now?

Of the 5 analysts covering electroCore, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks electroCore, Inc. 59 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ECOR?

As at 11 Sept 2026, electroCore, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (87 of 100).

Will ECOR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +106.3% from the last close, and Ticker Nerd's factor model ranks electroCore, Inc. 59 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ECOR stock forecast for 2030?

No analyst covering electroCore, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ECOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $26 over the next 12 months.

How has ECOR stock performed over the past year?

electroCore, Inc. returned +91.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does electroCore, Inc. do?

electroCore, Inc. is a commercial-stage bioelectronic medicine company that develops non-invasive vagus nerve stimulation (nVNS) products for healthcare and wellness use.

What is the latest news on ECOR?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "electroCore to Participate at H.C. Wainwright Global Investment Conference". electroCore, Inc. (Nasdaq: ECOR) announced that its management will participate in the H.C. Wainwright Global Investment Conference. The company is a commercial-stage bioelectronic medicine and wellness firm based in Rockaway, New Jersey.

Company

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company that develops non-invasive vagus nerve stimulation (nVNS) products for healthcare and wellness use. Its core offerings include gammaCore, a prescription handheld device used for primary headache conditions such as migraine and cluster headache, as well as Quell Fibromyalgia for chronic pain management. The company also markets Truvaga and TAC-STIM, consumer-focused nVNS products designed to support general wellness and human performance. electroCore’s technology platform is built around non-invasive neuromodulation, with products intended for both clinical and personal use across the United States, the United Kingdom, and international markets. Headquartered in Rockaway, New Jersey, electroCore serves a growing role in the medical device and bioelectronic therapy sectors by offering portable, non-surgical alternatives that address pain, wellness, and performance-related needs.

CEO Mr. Daniel S. Goldberger · 83 employees · United States · https://www.electrocore.com